Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

Overview of attention for article published in Frontiers in oncology, September 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 18,747 followers.

RT @FrontOncology: New research: Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small ce…

16 Sep 2023

Reply Repost Favourite

RT @FrontOncology: New research: Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small ce…

16 Sep 2023

Reply Repost Favourite

New research: Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study: Objective This study mainly observes… #oncology ht

16 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.